Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$204.93 -0.6%	$199.66	$153.58 ▼ $218.66	$362.52B	0.61	5.74 million shs	9.25 million shs
ABT Abbott Laboratories	$132.10 +0.3%	$131.03	$99.71 ▼ $141.23	$229.10B	0.7	5.85 million shs	4.23 million shs
IBB iShares Biotechnology ETF	$126.79 +1.9%	$135.64	$123.21 ▼ $150.57	$5.99B	0.84	1.32 million shs	1.66 million shs
JNJ Johnson & Johnson	$155.41 +1.4%	$159.36	$140.68 ▼ $169.99	$374.51B	0.47	7.71 million shs	10.35 million shs
PFE Pfizer	$24.73 +0.8%	$25.98	$24.31 ▼ $31.54	$140.26B	0.61	39.09 million shs	41.78 million shs

10 Stocks Set to Soar in Spring 2025

Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.56%	+1.87%	-3.00%	+14.21%	+13.40%
ABT Abbott Laboratories	+0.30%	+4.46%	-5.73%	+16.45%	+17.93%
IBB iShares Biotechnology ETF	+1.89%	-3.32%	-5.55%	-4.60%	-5.30%
JNJ Johnson & Johnson	+1.41%	-3.86%	-6.98%	+7.91%	-1.47%
PFE Pfizer	+0.84%	-1.84%	-5.65%	-7.07%	-10.24%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.5381 of 5 stars	2.5	3.0	3.3	3.9	3.4	2.5	1.3
ABT Abbott Laboratories	4.9016 of 5 stars	2.4	4.0	4.2	4.5	3.5	2.5	2.5
IBB iShares Biotechnology ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	4.7026 of 5 stars	3.3	3.0	4.2	3.9	3.2	2.5	0.6
PFE Pfizer	4.9865 of 5 stars	3.3	3.0	4.2	4.2	3.3	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.92	Moderate Buy	$211.45	3.18% Upside
ABT Abbott Laboratories	2.84	Moderate Buy	$137.94	4.42% Upside
IBB iShares Biotechnology ETF	2.70	Moderate Buy	$126.79	N/A
JNJ Johnson & Johnson	2.56	Moderate Buy	$171.33	10.25% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	29.09% Upside

Current Analyst Ratings Breakdown

Latest ABBV, JNJ, PFE, IBB, and ABT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2025	JNJ Johnson & Johnson	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00 ➝ $181.00
4/2/2025	JNJ Johnson & Johnson	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/17/2025	ABBV AbbVie	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/10/2025	ABT Abbott Laboratories	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$133.00 ➝ $150.00
3/10/2025	JNJ Johnson & Johnson	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/10/2025	PFE Pfizer	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/5/2025	ABBV AbbVie	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$210.00 ➝ $240.00
3/5/2025	JNJ Johnson & Johnson	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$159.00 ➝ $171.00
3/4/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$200.00 ➝ $223.00

(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	6.44	$15.15 per share	13.53	$1.90 per share	107.86
ABT Abbott Laboratories	$41.95B	5.46	$5.69 per share	23.22	$22.36 per share	5.91
IBB iShares Biotechnology ETF	N/A	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$88.82B	4.22	$12.77 per share	12.17	$29.69 per share	5.23
PFE Pfizer	$63.63B	2.20	$3.88 per share	6.38	$15.81 per share	1.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.40	85.39	14.66	1.62	7.59%	296.28%	12.65%	4/25/2025 (Estimated)
ABT Abbott Laboratories	$13.40B	$7.65	17.27	23.05	2.52	31.95%	20.74%	11.19%	4/16/2025 (Estimated)
IBB iShares Biotechnology ETF	N/A	N/A	27.83	∞	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$14.07B	$6.65	23.37	14.04	2.56	18.20%	34.24%	13.63%	4/15/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	17.54	8.16	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)

Latest ABBV, JNJ, PFE, IBB, and ABT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/29/2025	N/A	PFE Pfizer	$0.67	N/A	N/A	N/A	$14.43 billion	N/A
4/25/2025	N/A	ABBV AbbVie	$2.51	N/A	N/A	N/A	$12.91 billion	N/A
4/16/2025	N/A	ABT Abbott Laboratories	$1.07	N/A	N/A	N/A	$10.38 billion	N/A
4/15/2025	N/A	JNJ Johnson & Johnson	$2.59	N/A	N/A	N/A	$21.65 billion	N/A
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion
1/31/2025	Q4 24	ABBV AbbVie	$2.98	$2.16	-$0.82	-$0.02	$14.81 billion	N/A
1/22/2025	Q4 2024	ABT Abbott Laboratories	$1.34	$1.34	N/A	$5.27	$11.03 billion	$10.97 billion
1/22/2025	Q4 2024	JNJ Johnson & Johnson	$1.99	$2.04	+$0.05	$1.41	$22.44 billion	$22.52 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.20%	+6.04%	273.33%	53 Years
ABT Abbott Laboratories	$2.36	1.79%	+7.17%	30.85%	54 Years
IBB iShares Biotechnology ETF	$0.38	0.30%	N/A	N/A	N/A
JNJ Johnson & Johnson	$4.96	3.19%	+5.43%	74.59%	63 Years
PFE Pfizer	$1.72	6.96%	+2.50%	121.99%	16 Years

Latest ABBV, JNJ, PFE, IBB, and ABT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/13/2025	ABBV AbbVie	quarterly	$1.64	3.4%	4/15/2025	4/15/2025	5/15/2025
2/21/2025	ABT Abbott Laboratories	quarterly	$0.59	1.75%	4/15/2025	4/15/2025	5/15/2025
3/17/2025	IBB iShares Biotechnology ETF		$0.1212		3/18/2025	3/18/2025	3/21/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	17.94	0.66	0.55
ABT Abbott Laboratories	0.32	1.60	1.14
IBB iShares Biotechnology ETF	N/A	N/A	N/A
JNJ Johnson & Johnson	0.43	1.11	0.86
PFE Pfizer	0.63	1.00	0.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
ABT Abbott Laboratories	75.18%
IBB iShares Biotechnology ETF	62.45%
JNJ Johnson & Johnson	69.55%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.08%
ABT Abbott Laboratories	0.46%
IBB iShares Biotechnology ETF	N/A
JNJ Johnson & Johnson	0.16%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	50,000	1.77 billion	1.76 billion	Optionable
ABT Abbott Laboratories	115,000	1.73 billion	1.73 billion	Optionable
IBB iShares Biotechnology ETF	N/A	47.25 million	N/A	Optionable
JNJ Johnson & Johnson	152,700	2.41 billion	2.40 billion	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable

ABBV, JNJ, PFE, IBB, and ABT Headlines

Recent News About These Companies

Pfizer Inc. (NYSE:PFE) Shares Purchased by Huber Capital Management LLC

April 3 at 6:50 AM | marketbeat.com

Uniting Wealth Partners LLC Buys New Holdings in Pfizer Inc. (NYSE:PFE)

April 3 at 6:48 AM | marketbeat.com

Allen Wealth Management LLC Reduces Holdings in Pfizer Inc. (NYSE:PFE)

April 3 at 6:30 AM | marketbeat.com

OneAscent Financial Services LLC Acquires 11,447 Shares of Pfizer Inc. (NYSE:PFE)

April 3 at 5:48 AM | marketbeat.com

Cinctive Capital Management LP Has $4.81 Million Stock Position in Pfizer Inc. (NYSE:PFE)

April 3 at 5:47 AM | marketbeat.com

Is Pfizer Stock a Buy?

April 3 at 5:47 AM | fool.com

Huntington National Bank Sells 71,695 Shares of Pfizer Inc. (NYSE:PFE)

April 3 at 5:39 AM | marketbeat.com

2 Absurdly Cheap Stocks to Buy and Hold for Years

April 3 at 4:40 AM | fool.com

Pfizer (PFE) Increases Yet Falls Behind Market: What Investors Need to Know

April 2 at 6:50 PM | zacks.com

UK's Health Agency Endorses Pfizer's Blood Cancer Combo Therapy As First For Untreated Hodgkin Lymphoma Patients

April 2 at 4:32 PM | benzinga.com

Pfizer (NYSE:PFE) Shares Up 0.6% - Time to Buy?

April 2 at 1:19 PM | marketbeat.com

Pfizer (NYSE:PFE) Expands RSV Vaccine Use In Europe Amid 3% Share Price Dip

April 2 at 12:40 PM | finance.yahoo.com

PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters

April 2 at 10:46 AM | zacks.com

Pfizer (NYSE:PFE) Sets New 1-Year Low - What's Next?

April 2 at 10:29 AM | marketbeat.com

Proxy adviser ISS recommends Pfizer shareholders to vote against CEO compensation

April 2 at 9:10 AM | reuters.com

PFE Secures EU Nod for Expanded Use of RSV Vaccine Abrysvo

April 2 at 8:40 AM | zacks.com

Wall Street Says Sell US Market Rallies: Never Sell These 4 High-Yield Dividend Giants

April 2 at 7:47 AM | 247wallst.com

SevenBridge Financial Group LLC Sells 37,323 Shares of Pfizer Inc. (NYSE:PFE)

April 2 at 7:29 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Position Boosted by Private Portfolio Partners LLC

April 2 at 6:43 AM | marketbeat.com

Te Ahumairangi Investment Management Ltd Reduces Position in Pfizer Inc. (NYSE:PFE)

April 2 at 6:35 AM | marketbeat.com

Columbia Asset Management Sells 28,637 Shares of Pfizer Inc. (NYSE:PFE)

April 2 at 6:34 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
By Chris Markoch | March 23, 2025
View AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
3 Companies Buying Back Stock—Why It Matters
By Gabriel Osorio-Mazilli | March 12, 2025
View 3 Companies Buying Back Stock—Why It Matters
Resilient Investing: 3 Stocks Built to Weather Market Volatility
By Jeffrey Neal Johnson | March 17, 2025
View Resilient Investing: 3 Stocks Built to Weather Market Volatility
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
By Gabriel Osorio-Mazilli | April 1, 2025
View 2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

ABBV, JNJ, PFE, IBB, and ABT Company Descriptions

AbbVie NYSE:ABBV

$204.93 -1.34 (-0.65%)

Closing price 04/2/2025 03:58 PM Eastern

Extended Trading

$207.65 +2.72 (+1.33%)

As of 07:30 AM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Abbott Laboratories NYSE:ABT

$132.10 +0.41 (+0.31%)

Closing price 04/2/2025 03:58 PM Eastern

Extended Trading

$130.51 -1.59 (-1.20%)

As of 07:00 AM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

iShares Biotechnology ETF NASDAQ:IBB

$126.79 +2.35 (+1.89%)

Closing price 04/2/2025 04:00 PM Eastern

Extended Trading

$123.48 -3.31 (-2.61%)

As of 07:09 AM Eastern

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

Johnson & Johnson NYSE:JNJ

$155.41 +2.16 (+1.41%)

Closing price 04/2/2025 03:58 PM Eastern

Extended Trading

$155.87 +0.46 (+0.30%)

As of 07:30 AM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Pfizer NYSE:PFE

$24.73 +0.19 (+0.77%)

Closing price 04/2/2025 03:59 PM Eastern

Extended Trading

$24.54 -0.19 (-0.77%)

As of 07:31 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABBV, JNJ, PFE, IBB, and ABT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABBV, JNJ, PFE, IBB, and ABT Earnings

Compare Dividends

Latest ABBV, JNJ, PFE, IBB, and ABT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABBV, JNJ, PFE, IBB, and ABT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABBV, JNJ, PFE, IBB, and ABT Company Descriptions

AbbVie NYSE:ABBV

Abbott Laboratories NYSE:ABT

iShares Biotechnology ETF NASDAQ:IBB

Johnson & Johnson NYSE:JNJ

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools